vs
Guardant Health, Inc.（GH）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是Rapid7, Inc.的1.3倍（$281.3M vs $217.4M），Rapid7, Inc.净利率更高（1.4% vs -45.7%，领先47.1%），Guardant Health, Inc.同比增速更快（39.4% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $-54.2M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 3.0%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
GH vs RPD — 直观对比
营收规模更大
GH
是对方的1.3倍
$217.4M
营收增速更快
GH
高出38.8%
0.5%
净利率更高
RPD
高出47.1%
-45.7%
自由现金流更多
RPD
多$90.6M
$-54.2M
两年增速更快
GH
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $217.4M |
| 净利润 | $-128.5M | $3.1M |
| 毛利率 | 64.6% | 68.9% |
| 营业利润率 | -43.0% | 1.0% |
| 净利率 | -45.7% | 1.4% |
| 营收同比 | 39.4% | 0.5% |
| 净利润同比 | -15.8% | 44.1% |
| 每股收益（稀释后） | $-1.01 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRPD
| Q4 25 | $281.3M | $217.4M | ||
| Q3 25 | $265.2M | $218.0M | ||
| Q2 25 | $232.1M | $214.2M | ||
| Q1 25 | $203.5M | $210.3M | ||
| Q4 24 | $201.8M | $216.3M | ||
| Q3 24 | $191.5M | $214.7M | ||
| Q2 24 | $177.2M | $208.0M | ||
| Q1 24 | $168.5M | $205.1M |
净利润GHRPD
| Q4 25 | $-128.5M | $3.1M | ||
| Q3 25 | $-92.7M | $9.8M | ||
| Q2 25 | $-99.9M | $8.3M | ||
| Q1 25 | $-95.2M | $2.1M | ||
| Q4 24 | $-111.0M | $2.2M | ||
| Q3 24 | $-107.8M | $15.4M | ||
| Q2 24 | $-102.6M | $6.5M | ||
| Q1 24 | $-115.0M | $1.4M |
毛利率GHRPD
| Q4 25 | 64.6% | 68.9% | ||
| Q3 25 | 64.7% | 70.2% | ||
| Q2 25 | 65.0% | 70.6% | ||
| Q1 25 | 63.3% | 71.7% | ||
| Q4 24 | 61.6% | 69.5% | ||
| Q3 24 | 61.1% | 70.6% | ||
| Q2 24 | 59.1% | 70.7% | ||
| Q1 24 | 61.2% | 70.3% |
营业利润率GHRPD
| Q4 25 | -43.0% | 1.0% | ||
| Q3 25 | -37.3% | 2.7% | ||
| Q2 25 | -45.9% | 1.6% | ||
| Q1 25 | -54.6% | -0.0% | ||
| Q4 24 | -62.4% | 3.4% | ||
| Q3 24 | -61.3% | 6.0% | ||
| Q2 24 | -56.8% | 2.5% | ||
| Q1 24 | -59.2% | 4.7% |
净利率GHRPD
| Q4 25 | -45.7% | 1.4% | ||
| Q3 25 | -35.0% | 4.5% | ||
| Q2 25 | -43.0% | 3.9% | ||
| Q1 25 | -46.8% | 1.0% | ||
| Q4 24 | -55.0% | 1.0% | ||
| Q3 24 | -56.3% | 7.2% | ||
| Q2 24 | -57.9% | 3.1% | ||
| Q1 24 | -68.2% | 0.7% |
每股收益（稀释后）GHRPD
| Q4 25 | $-1.01 | $0.05 | ||
| Q3 25 | $-0.74 | $0.15 | ||
| Q2 25 | $-0.80 | $0.13 | ||
| Q1 25 | $-0.77 | $0.03 | ||
| Q4 24 | $-0.90 | $0.08 | ||
| Q3 24 | $-0.88 | $0.21 | ||
| Q2 24 | $-0.84 | $0.09 | ||
| Q1 24 | $-0.94 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $474.7M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $154.7M |
| 总资产 | $2.0B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHRPD
| Q4 25 | $378.2M | $474.7M | ||
| Q3 25 | $580.0M | $407.1M | ||
| Q2 25 | $629.1M | $511.7M | ||
| Q1 25 | $698.6M | $493.5M | ||
| Q4 24 | $525.5M | $521.7M | ||
| Q3 24 | $585.0M | $443.7M | ||
| Q2 24 | $933.7M | $442.6M | ||
| Q1 24 | $1.0B | $411.7M |
总债务GHRPD
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHRPD
| Q4 25 | $-99.3M | $154.7M | ||
| Q3 25 | $-354.5M | $127.2M | ||
| Q2 25 | $-305.5M | $90.4M | ||
| Q1 25 | $-250.8M | $52.7M | ||
| Q4 24 | $-139.6M | $17.7M | ||
| Q3 24 | $-60.1M | $-5.1M | ||
| Q2 24 | $-1.6M | $-52.6M | ||
| Q1 24 | $68.3M | $-86.4M |
总资产GHRPD
| Q4 25 | $2.0B | $1.7B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.6B | $1.5B | ||
| Q1 24 | $1.7B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $36.4M |
| 自由现金流率自由现金流/营收 | -19.3% | 16.8% |
| 资本支出强度资本支出/营收 | 9.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $-233.1M | $146.2M |
8季度趋势，按日历期对齐
经营现金流GHRPD
| Q4 25 | $-26.4M | $37.6M | ||
| Q3 25 | $-35.4M | $39.0M | ||
| Q2 25 | $-60.3M | $47.5M | ||
| Q1 25 | $-62.7M | $29.8M | ||
| Q4 24 | $-64.5M | $63.8M | ||
| Q3 24 | $-51.1M | $44.0M | ||
| Q2 24 | $-94.0M | $32.9M | ||
| Q1 24 | $-30.3M | $31.1M |
自由现金流GHRPD
| Q4 25 | $-54.2M | $36.4M | ||
| Q3 25 | $-45.8M | $34.8M | ||
| Q2 25 | $-65.9M | $46.6M | ||
| Q1 25 | $-67.1M | $28.4M | ||
| Q4 24 | $-83.4M | $62.6M | ||
| Q3 24 | $-55.3M | $42.6M | ||
| Q2 24 | $-99.1M | $32.6M | ||
| Q1 24 | $-37.2M | $30.4M |
自由现金流率GHRPD
| Q4 25 | -19.3% | 16.8% | ||
| Q3 25 | -17.3% | 16.0% | ||
| Q2 25 | -28.4% | 21.8% | ||
| Q1 25 | -33.0% | 13.5% | ||
| Q4 24 | -41.3% | 28.9% | ||
| Q3 24 | -28.9% | 19.9% | ||
| Q2 24 | -55.9% | 15.7% | ||
| Q1 24 | -22.1% | 14.8% |
资本支出强度GHRPD
| Q4 25 | 9.9% | 0.5% | ||
| Q3 25 | 3.9% | 1.9% | ||
| Q2 25 | 2.4% | 0.4% | ||
| Q1 25 | 2.2% | 0.6% | ||
| Q4 24 | 9.4% | 0.5% | ||
| Q3 24 | 2.2% | 0.6% | ||
| Q2 24 | 2.9% | 0.1% | ||
| Q1 24 | 4.1% | 0.3% |
现金转化率GHRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | — | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
